Merck & (MRK) Earnings Analysis

Merck & (MRK) next reports earnings on 2026-10-29, consensus EPS 2.27 USD. Last quarter (2026-04-30) it beat with EPS -1.28 USD vs -1.47 USD est (+12.9%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E 35.82.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MRK next report earnings?

Next earnings date2026-10-29
Consensus EPS estimate2.27 USD
Revenue estimate17.28B

MRK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-30-1.28 USD-1.47 USD+12.9%Beat
2026-02-032.04 USD2.01 USD+1.5%Beat
2025-10-302.58 USD2.36 USD+9.3%Beat
2024-10-311.57 USD1.5 USD+4.7%Beat

Beat rate: 4/4 (100%) over reported quarters with consensus data.

MRK valuation and analyst view

Trailing P/E35.82
Trailing EPS3.614 USD
Price / book6.87
Dividend yield2.63%
Market cap315.67B
Analyst consensusBuy (25 buy / 11 hold / 1 sell)
Avg price target140.71 USD

Related research pages

Frequently asked questions

When is Merck & (MRK)'s next earnings date?

Merck & is next scheduled to report on 2026-10-29, with a consensus EPS estimate of 2.27 USD and revenue estimate of 17.28B.

Did MRK beat earnings last quarter?

In its 2026-04-30 report, MRK posted EPS of -1.28 USD versus a -1.47 USD estimate — a beat of 12.9%.

What is MRK's earnings track record?

Over the last 4 reported quarters with consensus data, MRK beat estimates 4 times (100%).

What is MRK's current P/E ratio and EPS?

MRK trades at a trailing P/E of 35.82 on trailing EPS of 3.6144602682427087 USD.

What do analysts rate MRK?

Analyst consensus is "Buy" across 37 ratings (0 strong buy, 25 buy, 11 hold, 1 sell, 0 strong sell). Average 12-month price target: 140.71 USD.